<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1911246268
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Prokitav
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOLVAPTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30 + 60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        20397.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)	
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C03XA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Prokitav contains the active substance tolvaptan which blocks the effect of vasopressin, a hormone involved in the formation of cysts in the kidneys of ADPKD patients. By blocking the effect of vasopressin, Prokitav slows the development of kidney cysts in patients with ADPKD, reduces symptoms of the disease and increases urine production.</p><p>Prokitav is a medicine used to treat a disease called &ldquo;autosomal dominant polycystic kidney disease&rdquo; (ADPKD). This disease causes growth of fluid-filled cysts in the kidneys, which put pressure on surrounding tissues and reduce kidney function, possibly leading to kidney failure. Prokitav is used to treat ADPKD in adults with chronic kidney disease (CKD) stages 1 to 4 with evidence of rapidly progressing disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Prokitav </strong></p><ul><li>If you are allergic to tolvaptan or any of the other ingredients of this medicine (listed in section 6) or if you are allergic to benzazepine or benzazepine derivatives (e.g. benazepril, conivaptan, fenoldopam mesylate or mirtazapine)</li><li>If you have been told that you have raised levels of liver enzymes in your blood which do not allow treatment with tolvaptan</li><li>If your kidneys do not work (no urine production)</li><li>If you have a condition which is associated with a very low blood volume (e.g. severe dehydration or bleeding)</li><li>If you have a condition which increases the sodium in your blood</li><li>If you do not realise when you are thirsty</li><li>If you are pregnant</li><li>If you are breastfeeding.</li></ul><p><strong>Warnings and precautions</strong><br />Talk to your doctor before taking Prokitav</p><ul><li>If you suffer from liver disease.</li><li>If you cannot drink enough water (see &ldquo;drinking enough water&rdquo; below) or if you have to restrict your fluid intake.</li><li>If you have difficulties urinating (e.g. have an enlarged prostate).</li><li>If you suffer from too high or too low blood sodium.</li><li>If you had an allergic reaction in the past to benzazepine, tolvaptan or other benzazepine derivatives (e.g. benazepril, conivaptan, fenoldopam mesylate or mirtazapine), or to any of the other ingredients of this medicine (listed in section 6).</li><li>If you have diabetes.</li><li>If you have been told you have high levels of a chemical called uric acid in your blood (which may have caused attacks of gout).</li><li>If you have advanced kidney disease.</li></ul><p>This medicine may cause your liver to not work properly. Therefore, please inform your doctor immediately if you have signs that could indicate potential liver problems such as:</p><ul><li>Nausea</li><li>Vomiting</li><li>Fever</li><li>Tiredness</li><li>Loss of appetite</li><li>Pain in the abdomen</li><li>Dark urine</li><li>Jaundice (yellowing of skin or eyes)</li><li>Itching of your skin</li><li>Flu-like syndrome (joint and muscle pain with fever)</li></ul><p>During treatment with this medicine, your doctor will arrange monthly blood tests to check for changes in your liver function.</p><p><em>Drinking enough water</em><br />This medicine causes water loss because it increases your urine production. This water loss may result in side effects such as dry mouth and thirst or even more severe side effects like kidney problems (see section 4). It is therefore important that you have access to water and that you are able to drink sufficient amounts when you feel thirsty. Before bed-time you must drink 1 or 2 glasses of water even if you do not feel thirsty and you must also drink water after you urinate at night. Special care must be taken if you have a disease that reduces appropriate fluid intake or if you are at an increased risk of water loss e.g. in case of vomiting or diarrhoea. Due to the increased urine production, it is also important that you always have access to a toilet.</p><p><strong>Children and adolescents</strong><br />Do not give this medicine to children and adolescents (under age of 18 years) because it has not been studied in these age groups.</p><p><strong>Other medicines and Prokitav</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>The following medicines may increase the effect of Prokitav:</p><ul><li>Amprenavir, atazanavir, darunavir/ritonavir and fosamprenavir (used to treat HIV/AIDS),</li><li>Aprepitant (used to avoid nausea and vomiting in chemotherapy),</li><li>Crizotinib and imatinib (used to treat cancer),</li><li>Ketoconazole, fluconazole or itraconazole (used to treat fungal infections),</li><li>Macrolide antibiotics like erythromycin or clarithromycin,</li><li>Verapamil (used to treat heart diseases and high blood pressure),</li><li>Ciprofloxacin (an antibiotic),</li><li>Diltiazem (used to treat high blood pressure and chest pain).</li></ul><p>The following medicines may lower the effect of Prokitav:</p><ul><li>Phenytoin or carbamazepine (used to treat epilepsy),</li><li>Rifampicin, rifabutin or rifapentine (used to treat tuberculosis),</li><li>St. John&rsquo;s Wort (a traditional herbal medicinal product for the relief of slightly low mood and mild anxiety).</li></ul><p>Prokitav may increase the effect of the following medicines:</p><ul><li>Digoxin (used to treat irregular heart beat and heart failure),</li><li>Dabigatran (used to thin the blood),</li><li>Sulfasalazine (used to treat inflammatory bowel disease or rheumatoid arthritis),</li><li>Metformin (used to treat diabetes).</li></ul><p>Prokitav may lower the effect of the following medicines:</p><ul><li>Vasopressin analogues such as desmopressin (used to increase blood clotting factors or to control urine output or bedwetting).</li></ul><p>These medicines can affect or be affected by Prokitav:</p><ul><li>Diuretics (used to influence the production of urine). Taken with Prokitav these may increase the risk of side effects due to water loss or may cause kidney problems.</li><li>Diuretics or other medicines for the treatment of high blood pressure. Taken with Prokitav these may increase the risk of low blood pressure when you stand up from sitting or lying down.</li><li>Medicines which increase the level of sodium in your blood or which contain large amounts of salt (e.g. tablets that dissolve in water and indigestion remedies). These may increase the effect of Prokitav. There is a risk that this may lead to too much sodium in your blood.</li></ul><p>It may still be alright for you to take these medicines and Prokitav together. Your doctor will be able to decide what is suitable for you.</p><p><strong>Prokitav with food and drink</strong><br />Do not drink grapefruit juice when taking this medicine.</p><p><strong>Pregnancy and breast-feeding</strong><br />Do not take this medicine if you are pregnant or breast-feeding.</p><p>Women of childbearing age must use reliable contraceptive measures during use of this medicine.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines</strong><br />Some people may feel dizzy, weak or tired after being given tolvaptan. If this happens to you, do not drive or use any tools or machines.</p><p><strong>Prokitav contains lactose and sodium</strong><br />Prokitav contains lactose. Each tablet of Prokitav 15 mg, 30 mg, 45 mg, 60 mg and 90 mg Tablets contains 28 mg, 56 mg, 84 mg, 112 mg or 168 mg lactose; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>Prokitav contains sodium. Each tablet of Prokitav 15 mg, 30 mg, 45 mg, 60 mg and 90 mg Tablets contains 0.46 mg, 0.91 mg, 1.36 mg, 1.82 mg or 2.72 mg sodium; respectively. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Prokitav can only be prescribed by doctors who are specialised in the treatment of ADPKD. Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><em>Dose</em><br />The daily amount of Prokitav is split into two doses, one bigger than the other. The higher dose should be taken in the morning when you wake up, at least 30 minutes before the morning meal. The lower dose is taken 8 hours later.</p><p>The dose combinations are:<br />45 mg + 15 mg</p><p>60 mg + 30 mg</p><p>90 mg + 30 mg</p><p>Your treatment will normally start with a dose of 45 mg in the morning and 15 mg 8 hours later. Your doctor may gradually increase your dose up to a maximum combination of 90 mg on waking and 30 mg after 8 hours. To find the best dose your doctor will regularly check how well you are tolerating a prescribed dose. You should always take the highest tolerable dose combination prescribed by your doctor.</p><p>If you take other medicines, which can increase the effects of Prokitav you may receive lower doses. In this case your doctor may prescribe you Prokitav tablets with 30 mg or 15 mg tolvaptan which have to be taken once a day in the morning.</p><p><em>Method of administration</em><br />Swallow the tablets without chewing, with a glass of water.</p><p>The morning dose is to be taken at least 30 minutes before the morning meal. The second daily dose can be taken with or without food.</p><p><strong>If you take more Prokitav than you should</strong><br />If you have taken more tablets than your prescribed dose, drink plenty of water and contact your doctor or your local hospital immediately. Remember to take the medicine pack with you so that it is clear what you have taken. If you take the higher dose very late in the day you may have to go to the toilet at night more frequently.</p><p><strong>If you forget to take Prokitav</strong><br />If you forget to take your medicine, you should take the dose as soon as you remember on the same day. If you do not take your tablets on one day, take your normal dose on the next day. DO NOT take a double dose to make up for forgotten individual doses.</p><p><strong>If you stop taking Prokitav</strong><br />If you stop taking this medicine your kidney cysts may grow as fast as they did before you started treatment with Prokitav. Therefore, you should only stop taking this medicine if you notice side effects requiring urgent medical attention (see section 4) or if your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><em>Serious side effects:</em></strong><br /><strong>If you notice any of the following side effects, you may need urgent medical attention. Stop taking tolvaptan and immediately contact a doctor or go to the nearest hospital if you: </strong></p><ul><li>Find it difficult to urinate.</li><li>Experience swelling of the face, lips or tongue, itching, generalised rash, or severe wheezing or breathlessness (symptoms of an allergic reaction).</li></ul><p><strong>Tolvaptan may cause your liver not to work properly.</strong><br />Consult your doctor if symptoms of nausea, vomiting, fever, tiredness, loss of appetite, pain in the abdomen, dark urine, jaundice (yellowing of skin or eyes), itching of your skin or joint and muscle pain with fever occur.</p><p><strong><em>Other side effects:</em></strong><br /><strong>Very common (may affect more than 1 in 10 people) </strong></p><ul><li>Thirst (requiring excessive drinking of water)</li><li>Headache</li><li>Dizziness</li><li>Diarrhoea</li><li>Dry mouth</li><li>Increased need to urinate, to urinate at night, or to urinate more frequently</li><li>Fatigue</li></ul><p><strong>Common (may affect up to 1 in 10 people) </strong></p><ul><li>Dehydration</li><li>High levels of sodium, uric acid and blood sugar</li><li>Decreased appetite</li><li>Taste changes</li><li>Gout</li><li>Difficulty sleeping</li><li>Fainting</li><li>Heart pounding</li><li>Shortness of breath</li><li>Belly pain</li><li>Full or bloated or uncomfortable feeling in the stomach</li><li>Constipation</li><li>Heartburn</li><li>Liver function abnormal</li><li>Dry skin</li><li>Rash</li><li>Itching</li><li>Hives</li><li>Joint pain</li><li>Muscle spasms</li><li>Muscle pain</li><li>General weakness</li><li>Raised levels of liver enzymes in the blood</li><li>Weight loss</li><li>Weight gain</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people) </strong></p><ul><li>Increase of bilirubin (a substance that can cause yellowing of skin or eyes) in the blood</li></ul><p><strong>Not known (frequency cannot be estimated from the available data) </strong></p><ul><li>Allergic reactions (see above)</li><li>Generalised rash</li><li>Acute liver failure (ALF)</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p><p>Do not use this medicine after the expiry date which is stated on the outer package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is tolvaptan.</p><p>Each tablet of Prokitav 15 mg, 30 mg, 45 mg, 60 mg and 90 mg Tablets contains 15 mg, 30 mg, 45 mg, 60 mg or 90 mg tolvaptan; respectively.</p><p>The other ingredients are hypromellose, lactose, microcrystalline cellulose, croscarmellose sodium, maize starch, colloidal silicone dioxide, magnesium stearate, FD&amp;C blue and sodium lauryl sulfate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Prokitav may be provided in packs of 2 strengths as follows:
• Prokitav 45 mg and 15 mg Tablets:
Prokitav 45 mg Tablets are blue colored, round, biconvex tablets debossed with “T45” on one side and plain on the other side in PVC/Aclar-aluminum blisters.

Prokitav 15 mg Tablets are blue colored, round, biconvex tablets debossed with “T15” on one side and plain on the other side in PVC/Aclar-aluminum blisters.

• Prokitav 60 mg and 30 mg Tablets:
Prokitav 60 mg Tablets are blue colored, round, biconvex tablets debossed with “T60” on one side and plain on the other side in PVC/Aclar-aluminum blisters.

Prokitav 30 mg Tablets are blue colored, oval, biconvex tablets debossed with “T30” on one side and plain on the other side in PVC/Aclar-aluminum blisters.

• Prokitav 90 mg and 30 mg Tablets:
Prokitav 90 mg Tablets are blue colored, round, biconvex tablets debossed with “T90” on one side and plain on the other side in PVC/Aclar-aluminum blisters.

Prokitav 30 mg Tablets are blue colored, oval, biconvex tablets debossed with “T30” on one side and plain on the other side in PVC/Aclar-aluminum blisters.

Pack sizes: 
Prokitav 45 mg and 15 mg Tablets: 56 Tablets (28 tablets of the higher strength + 28 tablets of the lower strength).

Prokitav 60 mg and 30 mg Tablets: 56 Tablets (28 tablets of the higher strength + 28 tablets of the lower strength).

Prokitav 90 mg and 30 mg Tablets: 56 Tablets: (28 tablets of the higher strength + 28 tablets of the lower strength).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder, Bulk manufacturer and Batch releaser</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><p>&bull;&nbsp;&nbsp;United Arab of Emirates<br />Pharmacovigilance &amp; Medical Device Section<br />P.O. Box: 1853<br />Tel: 80011111<br />Email: pv@ede.gov.ae<br />Drug Department<br />Ministry of Health &amp; Prevention<br />Dubai</p><p>&bull;&nbsp;&nbsp; Saudi Arabia<br />The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />&bull;&nbsp;&nbsp; Other GCC States<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 12/2024; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بروكيتاﭫ على المادة الفعالة تولفابتان التي تمنع تأثير فازوبريسين، وهو هرمون يشارك في تكوين أكياس في الكلى لدى مرضى داء الكلى متعددة الأكياس الجسدي السائد الوراثي. عن طريق منع تأثير فازوبريسين، يبطئ بروكيتاﭫ من تطور أكياس الكلى لدى مرضى داء الكلى متعددة الأكياس الجسدي السائد الوراثي، ويقلل من أعراض المرض ويزيد من إنتاج البول.</p><p dir="RTL">بروكيتاﭫ هو دواء يستخدم لعلاج مرض يسمى &quot;داء الكلى متعددة الأكياس الجسدي السائد الوراثي&quot;. يتسبب هذا المرض في نمو الأكياس المليئة بالسوائل في الكلى، مما يضغط على الأنسجة المحيطة ويقلل من وظائف الكلى، والذي قد يؤدي إلى الفشل الكلوي. يستخدم بروكيتاﭫ لعلاج داء الكلى متعددة الأكياس الجسدي السائد الوراثي لدى البالغين المصابين بأمراض الكلى المزمنة في المراحل من 1 إلى 4 بوجود دليل على تطور المرض بسرعة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول بروكيتاﭫ&nbsp;</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لتولفابتان أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6) أو إذا كنت تعاني من حساسية لبنزازيبين أو مشتقاته (مثل بينازيبريل، كونيفابتان، ميسيلات الفينولدوبام أو ميرتازابين)</li><li>إذا قيل لك إنك تعاني من ارتفاع مستويات إنزيمات الكبد في دمك التي لا تسمح بالعلاج باستخدام تولفابتان</li><li>إذا كانت كُليتاك لا تعملان (لا تدران البول)</li><li>إذا كنت تعاني من حالة مرتبطة بانخفاض كبير في حجم الدم (مثل الجفاف الشديد أو النزف)</li><li>إذا كنت تعاني من حالة تزيد من نسبة الصوديوم في دمك</li><li>إذا كنت لا تدرك عندما تكون تشعر بالعطش</li><li>إذا كنتِ حاملاً</li><li>إذا كنتِ ترضعين بشكل طبيعي.</li></ul><p><strong>&nbsp;الاحتياطات والتحذيرات&nbsp;</strong><br />تحدث مع طبيبك قبل تناول بروكيتاﭫ</p><ul dir="rtl"><li>إذا كنت تعاني من مرض في الكبد.</li><li>إذا كنت لا تستطيع شرب كمية كافية من المياه (انظر &quot;شرب كمية كافية من المياه&quot; أدناه) أو إذا كان عليك الحد من شرب السوائل.</li><li>إذا كنت تواجه صعوبات في التبول (مثل الإصابة بتضخم البروستاتا).</li><li>إذا كنت تعاني من ارتفاع شديد أو انخفاض حاد في نسبة الصوديوم في الدم.</li><li>إذا كنت تعاني سابقاً من رد فعل تحسسي لبنزازيبين، تولفابتان أو أي من مشتقات بنزازيبين الأخرى (مثل بينازيبريل، كونيفابتان، ميسيلات الفينولدوبام أو ميرتازابين) أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li><li>إذا كنت مصاباً بمرض السكري.</li><li>إذا قيل لك إنك تعاني من ارتفاع مستويات مادة كيميائية تسمى حمض اليوريك في دمك (ربما تسببت في نوبات النقرس).</li><li>إذا كنت تعاني من أمراض في الكلى في مرحلة متقدمة.</li></ul><p dir="RTL">قد يتسبب هذا الدواء في عدم عمل الكبد كما ينبغي. لذلك، يرجى إبلاغ طبيبك فوراً في حال ظهور أعراض عليك قد تشير إلى مشاكل محتملة في الكبد مثل:</p><ul dir="rtl"><li>غثيان</li><li>قيء</li><li>حمّى</li><li>تعب</li><li>فقدان الشهية</li><li>ألم في البطن</li><li>بول داكن</li><li>يرقان (اصفرار الجلد أو العينين)</li><li>حكة بالجلد</li><li>متلازمة تشبه الإنفلونزا (ألم في المفاصل والعضلات مصحوباً بحمّى)</li></ul><p>أثناء العلاج بهذا الدواء، سيقوم طبيبك بترتيب اختبارات الدم الشهرية للتحقق من التغيرات في وظائف الكبد.</p><p><em>شرب كمية كافية من المياه&nbsp;</em><br />يتسبب هذا الدواء في فقدان المياه لأنه يزيد من إنتاج البول. قد يؤدي فقدان المياه هذا إلى آثار جانبية مثل جفاف الفم والعطش أو حتى آثار جانبية أكثر حدة مثل مشاكل الكلى (انظر القسم 4). لذلك من المهم أن تحصل على مياه وأن تتمكن من شرب الكميات الكافية عندما تشعر بالعطش. يجب أن تشرب كوباً أو كوبين من المياه قبل النوم حتى لو لم تشعر بالعطش ويجب أيضاً شرب المياه بعد التبول ليلاً. يجب إيلاء عناية خاصة إذا كان لديك مرض يقلل من كمية السوائل المناسبة أو إذا كنت معرضاً لخطر متزايد لفقدان المياه، على سبيل المثال، في حالة القيء أو الإسهال. نظراً لزيادة إنتاج البول، من المهم أيضاً أن تتمكن دوماً من دخول المرحاض.</p><p><strong>الأطفال والمراهقون&nbsp;</strong><br />لا تعطِ هذا الدواء للأطفال والمراهقين (أقل من 18 عاماً) نظراً لعدم إجراء أي دراسات بخصوص تأثير الدواء على هذه الفئة العمرية.</p><p dir="RTL"><strong>الأدوية الأخرى وبروكيتاﭫ&nbsp;</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أخذت مؤخراً، أو قد تأخذ أية أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p>قد تزيد الأدوية التالية من التأثير الذي يحدثه بروكيتاﭫ:</p><ul dir="rtl"><li>أمبرينافير، أتازانافير ودارونافير/ريتونافير وفوسامبرينافير (يُستخدم لعلاج فيروس نقص المناعة البشري/الإيدز)،</li><li>أبريبيتانت (يُستخدم لمنع الغثيان والقيء الناجمان عن العلاج الكيميائي)،</li><li>كريزتونيب وإيماتينب (يُستخدمان لعلاج السرطان)،</li><li>كيتوكونازول، فلوكونازول أو إيتراكونازول (تُستخدم لعلاج العدوى الفطرية)،</li><li>المضادات الحيوية من مجموعة الماكرولايد مثل أريثروميسين أو كلاريثرومايسين،</li><li>فيراباميل (يُستخدم لعلاج أمراض القلب وارتفاع ضغط الدم)،</li><li>سيبروفلوكساسين (مضاد حيوي)،</li><li>ديلتيازيم (يُستخدم لعلاج ارتفاع ضغط الدم وألم الصدر).</li></ul><p>قد تقلل الأدوية التالية من التأثير الذي يحدثه بروكيتاﭫ:</p><ul dir="rtl"><li>فينيتوين أو كاربامازيبين (يُستخدم في علاج الصرع)،</li><li>ريفامبيسين، ريفابوتين أو ريفابنتين (يُستخدم لعلاج مرض السل)،</li><li>نبتة سانت جون (منتج طبي عشبي تقليدي لتخفيف انخفاض الحالة المزاجية والقلق الخفيف).</li></ul><p>قد يعمل بروكيتاﭫ على زيادة تأثير الأدوية التالية:</p><ul dir="rtl"><li>ديجوكسين (يُستخدم لعلاج عدم انتظام نبضات القلب وفشل القلب)،</li><li>دابيغاتران (يُستخدم لترقيق الدم)،</li><li>سلفاسالازين (يُستخدم لعلاج مرض التهاب الأمعاء أو التهاب المفاصل الروماتويدي)،</li><li>ميتفورمين (يُستخدم لعلاج مرض السكري).</li></ul><p>قد يعمل بروكيتاﭫ على تقليل تأثير الأدوية التالية:</p><ul dir="rtl"><li>أدوية الفازوبريسين المثيلة مثل ديسموبريسين (يُستخدم لزيادة عوامل تخثر الدم أو للتحكم في إنتاج البول أو التبول في الفراش).</li></ul><p>يمكن أن تؤثر الأدوية التالية على بروكيتاﭫ أو تتأثر به:</p><ul dir="rtl"><li>مدرات البول (تُستخدم للتأثير على إنتاج البول). قد يؤدي تناولها مع بروكيتاﭫ إلى زيادة خطر حدوث آثار جانبية بسبب فقدان المياه أو قد يسبب مشاكل في الكلى.</li><li>مدرات البول أو الأدوية الأخرى لعلاج ارتفاع ضغط الدم. قد يؤدي تناولها مع بروكيتاﭫ إلى زيادة خطر انخفاض ضغط الدم عند الوقوف من وضعية الجلوس أو الاستلقاء.</li><li>الأدوية التي تزيد من مستوى الصوديوم في الدم أو التي تحتوي على كميات كبيرة من الملح (مثل الأقراص التي تذوب في المياه وعلاجات عسر الهضم). قد تزيد هذه الأدوية من التأثير الذي يحدثه بروكيتاﭫ. هناك خطر أن يؤدي ذلك إلى وجود الكثير من الصوديوم في دمك.</li></ul><p>قد يكون من الجيد لك تناول هذه الأدوية مع بروكيتاﭫ. سيكون طبيبك قادراً على تحديد ما هو مناسب لحالتك.</p><p><strong>بروكيتاﭫ مع الطعام والشراب&nbsp;</strong><br />لا تشرب عصير الجريب فروت عند تناول هذا الدواء.</p><p><strong>الحمل والرضاعة&nbsp;</strong><br />لا تتناولي هذا الدواء إذا كنتِ حاملاً أو ترضعين طبيعياً.</p><p>يجب على النساء في سن الإنجاب استخدام وسائل موثوقة لمنع الحمل أثناء استخدام هذا الدواء.</p><p>استشيري طبيبك أو الصيدلي إذا كنتِ حاملاً أو مرضعاً، تعتقدين بأنكِ حامل أو تخططين لذلك.</p><p><strong>القيادة واستخدام الآلات&nbsp;</strong><br />قد يشعر بعض الأشخاص بالدوخة، الضعف أو التعب بعد إعطائهم تولفابتان. إذا حدث ذلك لك، تجنب القيادة أو استخدام أي أدوات أو آلات.</p><p dir="RTL"><strong>يحتوي بروكيتاﭫ</strong> <strong>على</strong><strong> اللاكتوز والصوديوم&nbsp;</strong><br />يحتوي بروكيتاﭫ على اللاكتوز. يحتوي كل قرص من بروكيتاﭫ 15 ملغم، 30 ملغم، 45 ملغم، 60 ملغم و90 ملغم أقراص على 28 ملغم، 56 ملغم، 84 ملغم، 112 ملغم أو 168 ملغم لاكتوز؛ على التوالي. إذا أخبرك طبيبك بأن لديك عدم تحمل لبعض السكريات، تواصل مع طبيبك قبل تناول هذا المستحضر الدوائي.</p><p dir="RTL">يحتوي<strong> </strong>بروكيتاﭫ على الصوديوم. يحتوي كل قرص من بروكيتاﭫ 15 ملغم، 30 ملغم، 45 ملغم، 60 ملغم و90 ملغم أقراص على 0,46 ملغم، 0,91 ملغم، 1,36 ملغم، 1,82 ملغم أو 2,72 ملغم صوديوم؛ على التوالي. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل قرص، بمعنى أنه &rsquo;خال من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن وصف بروكيتاﭫ فقط من قِبل الأطباء المتخصصين في علاج داء الكلى متعددة الأكياس الجسدي السائد الوراثي. قم دائماً بتناول هذا الدواء كما أخبرك طبيبك تماماً. تحقق من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p><em>الجرعة&nbsp;</em><br />يُقسَّم المقدار اليومي من بروكيتاﭫ إلى جرعتين، إحداهما أكبر من الأخرى. يجب تناول الجرعة الأكبر في الصباح عند الاستيقاظ، قبل 30 دقيقة على الأقل من الإفطار. ويتم تناول الجرعة الأصغر بعد 8 ساعات من ذلك الوقت.</p><p>تراكيب الجرعات هي:&nbsp;<br />45 ملغم + 15 ملغم</p><p dir="RTL">60 ملغم + 30 ملغم</p><p dir="RTL">90 ملغم + 30 ملغم</p><p>سيبدأ علاجك عادةً بجرعة 45 ملغم في الصباح وأخرى 15 ملغم بعد 8 ساعات من ذلك الوقت. قد يزيد طبيبك تركيبة جرعتك تدريجياً حتى 90 ملغم كحد أقصى عند الاستيقاظ و30 ملغم بعد 8 ساعات من ذلك الوقت. سيتحقق طبيبك بانتظام من مدى تحملك للجرعة الموصوفة لإيجاد أنسب جرعة. يجب عليك دائماً تناول أكثر تركيبة جرعة يمكنك تحملها يصفها طبيبك.</p><p>إذا كنت تتناول أدوية أخرى، والتي يمكن أن تزيد من تأثيرات بروكيتاﭫ، فقد تتلقى جرعات أقل. في هذه الحالة، قد يصف لك طبيبك أقراص بروكيتاﭫ مع تولفابتان 30 ملغم أو 15 ملغم التي يجب أن تؤخذ مرة واحدة في اليوم في الصباح.</p><p><em>طريقة إعطاء الدواء&nbsp;</em><br />ابتلع الأقراص دون مضغ مع كوب من المياه.</p><p>يجب تناول جرعة الصباح قبل 30 دقيقة على الأقل من الإفطار. يمكن تناول الجرعة اليومية الثانية مع الطعام أو بدونه.</p><p><strong>إذا تناولت بروكيتاﭫ أكثر من اللازم&nbsp;</strong><br />إذا تناولت أقراصاً تزيد عن الجرعة الموصوفة لك، اشرب الكثير من الماء وتواصل مع طبيبك أو المستشفى المحلي فوراً. تذكر أن تأخذ علبة الدواء معك حتى يتضح نوع الدواء الذي تناولته. إذا تناولت الجرعة الأكبر في وقت متأخر للغاية من اليوم، فقد تضطر إلى الذهاب للمرحاض في الليل بشكل متكرر.</p><p dir="RTL"><strong>إذا نسيت تناول بروكيتاﭫ&nbsp;</strong><br />إذا نسيت تناول دوائك، يجب عليك تناول الجرعة بمجرد تذكرها في نفس اليوم. إذا لم تتناول الأقراص الموصوفة لك في أحد الأيام، فتناول جرعتك العادية في اليوم التالي. لا تقم بتناول جرعة مضاعفة لتعويض الجرعات المنسية.</p><p><strong>إذا توقفت عن تناول بروكيتاﭫ&nbsp;</strong><br />إذا توقفت عن تناول هذا الدواء، فقد تنمو أكياس الكلى بالسرعة التي كانت عليها قبل أن تبدأ العلاج باستخدام بروكيتاﭫ. وعليه، لا يجب عليك التوقف عن تناول هذا الدواء إلا إذا لاحظت آثاراً جانبية تتطلب عناية طبية طارئة (انظر القسم 4) أو إذا أخبرك طبيبك بذلك.</p><p>إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا إنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p><strong><em>الآثار الجانبية الخطيرة:&nbsp;</em></strong><br /><strong>إذا لاحظت أياً من الآثار الجانبية التالية، فقد تحتاج إلى تلقي العناية الطبية الطارئة. توقف عن تناول تولفابتان وتواصل فوراً مع طبيب أو توجه إلى أقرب مستشفى إذا كنت: </strong></p><ul dir="rtl"><li>تواجه مشكلة في التبول.</li><li>تشعر بتورم في الوجه، الشفتين أو اللسان، حكة، طفح جلدي عام، أو صفير حاد أو ضيق في التنفس (أعراض رد فعل تحسسي).</li></ul><p><strong>قد يتسبب تولفابتان في عدم عمل الكبد كما ينبغي.&nbsp;</strong><br />استشر طبيبك إذا ظهرت أعراض غثيان، قيء، حمّى، تعب أو فقدان شهية، ألم في البطن، بول داكن، يرقان (اصفرار الجلد أو العينين)، حكة في الجلد أو ألم في المفاصل والعضلات مصحوباً بحمّى.</p><p><strong><em>الآثار الجانبية الأخرى:&nbsp;</em></strong><br /><strong>شائعة جداً (قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص) </strong></p><ul dir="rtl"><li>عطش (يتطلب شرب كمية كبيرة من المياه)</li><li>صداع</li><li>دوخة</li><li>إسهال</li><li>جفاف الفم</li><li>زيادة الحاجة إلى التبول، التبول في الليل، أو التبول بشكل متكرر</li><li>إرهاق</li></ul><p><strong>شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص) </strong></p><ul dir="rtl"><li>جفاف</li><li>ارتفاع مستويات الصوديوم، حمض اليوريك وسكر الدم</li><li>نقص الشهية</li><li>تغيرات في حاسة التذوق</li><li>النقرس</li><li>صعوبة في النوم</li><li>إغماء</li><li>خفقان القلب</li><li>ضيق التنفس</li><li>ألم في البطن</li><li>شعور بالامتلاء أو الانتفاخ أو عدم الارتياح في المعدة</li><li>إمساك</li><li>حرقة في المعدة</li><li>وظائف كبد غير طبيعية</li><li>جفاف الجلد</li><li>طفح جلدي</li><li>حكة</li><li>شرى</li><li>ألم في المفاصل</li><li>تشنجات عضلية</li><li>ألم في العضلات</li><li>ضعف عام</li><li>ارتفاع مستويات إنزيمات الكبد في الدم</li><li>فقدان في الوزن</li><li>زيادة الوزن</li></ul><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص) </strong></p><ul dir="rtl"><li>زيادة البيليروبين (مادة قد تسبب اصفرار الجلد أو العينين) في الدم</li></ul><p><strong>غير معروفة (لا يمكن تقدير التكرار من البيانات المتاحة) </strong></p><ul dir="rtl"><li>ردود فعل تحسسية (انظر أعلاه)</li><li>طفح جلدي عام</li><li>فشل كبدي حاد</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء والرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي تولفابتان.</p><p dir="RTL">يحتوي كل قرص من بروكيتاﭫ 15 ملغم، 30 ملغم، 45 ملغم، 60 ملغم و90 ملغم أقراص على 15 ملغم، 30 ملغم، 45 ملغم، 60 ملغم أو90 ملغم تولفابتان؛ على التوالي.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي هيبروميللوز، لاكتوز، سيلليلوز بلوري مكروي، كروسكارميللوز الصوديوم، نشا الذرة، ثاني أكسيد السيليكون الغروي، ستيرات المغنيسيوم، صبغة FD&amp;C زرقاء وكبريتات لوريل الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يتوفر بروكيتاﭫ بعبوات تحتوي على تركيزين كالتالي:</p><ul dir="rtl"><li><em>&nbsp;</em><em>بروكيتاﭫ 45 ملغم و15 ملغم أقراص:</em></li></ul><p dir="RTL">بروكيتاﭫ 45 ملغم أقراص هي أقراص زرقاء اللون، دائرية، محدبة الوجهين محفور عليها &quot;T45&quot; على جهة واحدة وملساء على الجهة الأخرى في أشرطة من كلوريد متعدد الڤينيل/أكلار-الألمنيوم.</p><p dir="RTL">بروكيتاﭫ 15 ملغم أقراص هي أقراص زرقاء اللون، دائرية، محدبة الوجهين محفور عليها &quot;T15&quot; على جهة واحدة وملساء على الجهة الأخرى في أشرطة من كلوريد متعدد الڤينيل/أكلار-الألمنيوم.</p><ul dir="rtl"><li><em>بروكيتاﭫ 60 ملغم و30 ملغم أقراص:</em></li></ul><p dir="RTL">بروكيتاﭫ 60 ملغم أقراص هي أقراص زرقاء اللون، دائرية، محدبة الوجهين محفور عليها &quot;T60&quot; على جهة واحدة وملساء على الجهة الأخرى في أشرطة من كلوريد متعدد الڤينيل/أكلار-الألمنيوم.</p><p dir="RTL">بروكيتاﭫ 30 ملغم أقراص هي أقراص زرقاء اللون، بيضاوية، محدبة الوجهين محفور عليها &quot;T30&quot; على جهة واحدة وملساء على الجهة الأخرى في أشرطة من كلوريد متعدد الڤينيل/أكلار-الألمنيوم.</p><ul dir="rtl"><li><em>&nbsp;</em><em>بروكيتاﭫ 90 ملغم و30 ملغم أقراص:</em></li></ul><p dir="RTL">بروكيتاﭫ 90 ملغم أقراص هي أقراص زرقاء اللون، دائرية، محدبة الوجهين محفور عليها &quot;T90&quot; على جهة واحدة وملساء على الجهة الأخرى في أشرطة من كلوريد متعدد الڤينيل/أكلار-الألمنيوم.</p><p dir="RTL">بروكيتاﭫ 30 ملغم أقراص هي أقراص زرقاء اللون، بيضاوية، محدبة الوجهين محفور عليها &quot;T30&quot; على جهة واحدة وملساء على الجهة الأخرى في أشرطة من كلوريد متعدد الڤينيل/أكلار-الألمنيوم.</p><p dir="RTL">أحجام العبوات:&nbsp;<br />بروكيتاﭫ 45 ملغم و15 ملغم أقراص: 56 قرص (28 قرص من التركيز الأعلى + 28 قرص من التركيز الأقل).</p><p dir="RTL">بروكيتاﭫ 60 ملغم و30 ملغم أقراص: 56 قرص (28 قرص من التركيز الأعلى + 28 قرص من التركيز الأقل).</p><p dir="RTL">بروكيتاﭫ 90 ملغم و30 ملغم أقراص: 56 قرص (28 قرص من التركيز الأعلى + 28 قرص من التركيز الأقل).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong><strong>، الشركة المصنعة للستحضر النهائي ومحرر التشغيلة&nbsp;</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية&nbsp;</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL">&bull;&nbsp;الإمارات العربية المتحدة<br />قسم اليقظة الدوائية والجهاز الطبي<br />صندوق بريد: 1853<br />هاتف: 80011111<br />البريد الإلكتروني: pv@ede.gov.ae<br />إدارة الدواء<br />وزارة الصحة ووقاية المجتمع<br />دبي</p><p dir="RTL">&bull; المملكة العربية السعودية<br />المركز الوطني للتيقظ الدوائي<br />مركز الاتصال الموحد: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: https://ade.sfda.gov.sa<br />&bull;&nbsp;دول الخليج العربي الأخرى<br />الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 12/2024؛ رقم النسخة SA2.0.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prokitav 60 mg and 30 mg Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet of Prokitav 60 mg Tablets contains 60 mg tolvaptan.

Each tablet of Prokitav 30 mg Tablets contains 30 mg tolvaptan.

Excipients with known effect: Lactose and sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets.

Prokitav 60 mg Tablets
Blue colored, round, biconvex tablets debossed with “T60” on one side and plain on the other side.

Prokitav 30 mg Tablets
Blue colored, oval, biconvex tablets debossed with “T30” on one side and plain on the other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prokitav is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease (see section 5.1).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tolvaptan treatment must be initiated and monitored under the supervision of physicians with expertise in managing ADPKD and a full understanding of the risks of tolvaptan therapy including hepatic toxicity and monitoring requirements (see section 4.4).</p><p><strong><em>Posology</em></strong><br />Prokitav is to be administered twice daily in split dose regimens of 45 mg + 15 mg, 60 mg + 30 mg or 90 mg + 30 mg. The morning dose is to be taken at least 30 minutes before the morning meal. The second daily dose can be taken with or without food. According to these split dose regimens the total daily doses are 60 mg, 90 mg, or 120 mg.</p><p><strong>Dose titration</strong><br />The initial dose is 60 mg tolvaptan per day as a split-dose regimen of 45 mg + 15 mg (45 mg taken upon waking and prior the morning meal and 15 mg taken 8 hours later). The initial dose is to be titrated upward to a split-dose regimen of 90 mg tolvaptan (60 mg + 30 mg) per day and then to a target split-dose regimen of 120 mg tolvaptan (90 mg + 30 mg) per day, if tolerated, with at least weekly intervals between titrations. Dose titration has to be performed cautiously to ensure that high doses are not poorly tolerated through overly rapid up-titration. Patients may down-titrate to lower doses based on tolerability. Patients have to be maintained on the highest tolerable tolvaptan dose.</p><p>The aim of dose titration is to block activity of vasopressin at the renal V2 receptor as completely and constantly as possible, while maintaining acceptable fluid balance (see section 4.4).</p><p>Measurements of urine osmolality are recommended to monitor the adequacy of vasopressin inhibition. Periodic monitoring of plasma osmolality or serum sodium (to calculate plasma osmolarity) and/or body weight should be considered to monitor the risk of dehydration secondary to the aquaretic effects of tolvaptan in case of patient&rsquo;s insufficient water intake.</p><p>The safety and efficacy of tolvaptan in CKD stage 5 have not been explored and therefore tolvaptan treatment should be discontinued if renal insufficiency progresses to CKD stage 5 (see section 4.4).</p><p>Therapy must be interrupted if the ability to drink or the accessibility to water is limited (see section 4.4).</p><p>Tolvaptan must not be taken with grapefruit juice (see section 4.5). Patients must be instructed to drink sufficient amounts of water or other aqueous fluids (see section 4.4).</p><p><strong>Dose adjustment for patients taking strong CYP3A inhibitorsu</strong><br />In patients taking strong CYP3A inhibitors (see section 4.5), tolvaptan doses have to be reduced as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Tolvaptan daily split-dose</p></td><td><p>Reduced dose (once daily)</p></td></tr><tr><td><p>90 mg + 30 mg</p></td><td><p>30 mg (further reduction to 15 mg if 30 mg are not well tolerated)</p></td></tr><tr><td><p>60 mg + 30 mg</p></td><td><p>30 mg (further reduction to 15 mg if 30 mg are not well tolerated)</p></td></tr><tr><td><p>45 mg + 15 mg</p></td><td><p>15 mg</p></td></tr></tbody></table><p><strong>Dose adjustment for patients taking moderate CYP3A inhibitors</strong><br />In patients taking moderate CYP3A inhibitors, tolvaptan doses have to be reduced as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Tolvaptan daily split-dose</p></td><td><p>Reduced split-dose</p></td></tr><tr><td><p>90 mg + 30 mg</p></td><td><p>45 mg + 15 mg</p></td></tr><tr><td><p>60 mg + 30 mg</p></td><td><p>30 mg + 15 mg</p></td></tr><tr><td><p>45 mg + 15 mg</p></td><td><p>15 mg + 15 mg</p></td></tr></tbody></table><p>Further reductions have to be considered if patients cannot tolerate the reduced tolvaptan doses.</p><p><strong><em>Special populations</em></strong><br /><strong>Elderly population</strong><br />Increasing age has no effect on tolvaptan plasma concentrations. Limited data on the safety and effectiveness of tolvaptan in ADPKD patients aged over 55 are available (see section 5.1).</p><p><strong>Renal impairment</strong><br />Tolvaptan is contraindicated in anuric patients (see section 4.3).</p><p>Dose adjustment is not required in patients with renal impairment.</p><p>No clinical trials in subjects with indices of glomerular filtration rate &lt; 10 ml/min or in patients undergoing dialysis have been conducted. The risk of hepatic damage in patients with severely reduced renal function (i.e. estimated glomerular filtration rate [eGFR] &lt; 20) may be increased; these patients should be carefully monitored for hepatic toxicity. Data for patients in CKD early stage 4 are more limited than for patients in stage 1, 2 or 3 (see section 5.1). Limited data are available for patients with CKD late stage 4 (eGFR &lt; 25 ml/min/1.73 m<sup>2</sup>). No data are available for patients with CKD stage 5. Tolvaptan treatment should be discontinued if renal insufficiency progresses to CKD stage 5 (see section 4.4).</p><p><strong>Hepatic impairment</strong><br />In patients with severe hepatic impairment the benefits and risks of treatment with Prokitav must be evaluated carefully. Patients must be managed carefully and liver enzymes must be monitored regularly (see section 4.4).</p><p>Prokitav is contraindicated in patients with elevated liver enzymes and/or signs or symptoms of liver injury prior to initiation of treatment that meet the requirements for permanent discontinuation of tolvaptan (see sections 4.3 and 4.4).</p><p>No dose adjustment is needed in patients with mild or moderate hepatic impairment (Child-Pugh classes A and B).</p><p><strong>Paediatric</strong> <strong>population</strong><br />The safety and efficacy of tolvaptan in children and adolescents has not yet been established. No data are available. Tolvaptan is not recommended in the paediatric age group.</p><p><strong><em>Method of administration</em></strong><br />Oral use.</p><p>Tablets must be swallowed without chewing and with a glass of water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to benzazepine or benzazepine derivatives (see section 4.4) 
• Elevated liver enzymes and/or signs or symptoms of liver injury prior to initiation of treatment that meet the requirements for permanent discontinuation of tolvaptan (see section 4.4) 
• Anuria 
• Volume depletion 
• Hypernatraemia 
• Patients who cannot perceive or respond to thirst 
• Pregnancy (see section 4.6) 
• Breast-feeding (see section 4.6)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Idiosyncratic hepatic toxicity</strong><br />Tolvaptan has been associated with idiosyncratic elevations of blood alanine and aspartate aminotransferases (ALT and AST) with infrequent cases of concomitant elevations in bilirubin-total (BT).</p><p>In post-marketing experience with tolvaptan in ADPKD, acute liver failure requiring liver transplantation has been reported.</p><p>In a double-blind, placebo-controlled trial in patients with ADPKD, the period of onset of hepatocellular injury (by ALT elevations &gt; 3 &times; ULN) was within 3 to 14 months after initiating treatment and these increases were reversible, with ALT returning to &lt; 3 &times; ULN within 1 to 4 months. While these concomitant elevations were reversible with prompt discontinuation of tolvaptan, they represent a potential for significant liver injury. Similar changes with other medicinal products have been associated with the potential to cause irreversible and potentially life-threatening liver injury (see section 4.8).</p><p><u>Prescribing physicians must comply fully with the safety measures required below.</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>To mitigate the risk of significant and/or irreversible liver injury, blood testing for hepatic transaminases and bilirubin is required prior to initiation of Prokitav, continuing monthly for 18 months and at regular 3-monthly intervals thereafter. Concurrent monitoring for symptoms that may indicate liver injury (such as fatigue, anorexia, nausea, right upper abdominal discomfort, vomiting, fever, rash, pruritus, dark urine or jaundice) is recommended.</p><p>If a patient shows abnormal ALT, AST or BT levels prior to initiation of treatment which fulfil the criteria for permanent discontinuation (see below), the use of tolvaptan is contraindicated (see section 4.3). In case of abnormal baseline levels below the limits for permanent discontinuation treatment can only be initiated if the potential benefits of treatment outweigh the potential risks and liver function testing must continue at increased time frequency. The advice of a hepatologist is recommended.</p><p>During the first 18 months of treatment, Prokitav can only be supplied to patients whose physician has determined that liver function supports continued therapy.</p><p>At the onset of symptoms or signs consistent with hepatic injury or if clinically significant abnormal ALT or AST increases are detected during treatment, Prokitav administration must be immediately interrupted and repeat tests including ALT, AST, BT and alkaline phosphatase (AP) must be obtained as soon as possible (ideally within 48 hours to 72 hours). Testing must continue at increased time frequency until symptoms/signs/laboratory abnormalities stabilise or resolve, at which point Prokitav may be re-initiated.</p><p>Current clinical practice suggests that tolvaptan therapy is to be interrupted upon confirmation of sustained or increasing transaminase levels and permanently discontinued if significant increases and/or clinical symptoms of hepatic injury persist.</p><p>Recommended guidelines for permanent discontinuation include:</p><p>&bull;&nbsp;&nbsp; ALT or AST &gt; 8-times ULN</p><p>&bull;&nbsp;&nbsp; ALT or AST &gt; 5-times ULN for more than 2 weeks</p><p>&bull;&nbsp;&nbsp; ALT or AST &gt; 3-times ULN and (BT &gt; 2-times ULN or International Normalised Ratio [INR] &gt; 1.5)</p><p>&bull;&nbsp;&nbsp; ALT or AST &gt; 3-times ULN with persistent symptoms of hepatic injury noted above.</p><p>If ALT and AST levels remain below 3-times the ULN, tolvaptan therapy may be cautiously re-started, with frequent monitoring at the same or lower doses, as transaminase levels appear to stabilise during continued therapy in some patients.</p></td></tr></tbody></table><p><strong>Access to water</strong><br />Tolvaptan may cause adverse reactions related to water loss such as thirst, polyuria, nocturia, and pollakiuria (see section 4.8). Therefore, patients must have access to water (or other aqueous fluids) and be able to drink sufficient amounts of these fluids (see section 4.2). Patients have to be instructed to drink water or other aqueous fluids at the first sign of thirst in order to avoid excessive thirst or dehydration.</p><p>Additionally, patients have to drink 1 to 2 glasses of fluid before bedtime regardless of perceived thirst and replenish fluids overnight with each episode of nocturia.</p><p><strong>Dehydration</strong><br />Volume status must be monitored in patients taking tolvaptan because treatment with tolvaptan may result in severe dehydration which constitutes a risk factor for renal dysfunction. Accurate monitoring of body weight is recommended. A progressive reduction in body weight could be an early sign of progressive dehydration. If dehydration becomes evident, take appropriate action, which may include the need to interrupt or reduce the dose of tolvaptan and increase fluid intake. Special care must be taken in patients having diseases that impair appropriate fluid intake or who are at an increased risk of water loss e.g. in case of vomiting or diarrhoea.</p><p><strong>Urinary outflow obstruction</strong><br />Urinary output must be secured. Patients with partial obstruction of urinary outflow, for example patients with prostatic hypertrophy or impairment of micturition, have an increased risk of developing acute retention.</p><p><strong>Fluid and electrolyte balance</strong><br />Fluid and electrolyte status must be monitored in all patients. Administration of tolvaptan induces copious aquaresis and may cause dehydration and increases in serum sodium (see section 4.8) and is contraindicated in hypernatraemic patients (see section 4.3). Therefore, serum creatinine, electrolytes and symptoms of electrolyte imbalances (e.g. dizziness, fainting, palpitations, confusion, weakness, gait instability, hyper-reflexia, seizures, coma) have to be assessed prior to and after starting tolvaptan to monitor for dehydration.</p><p>During long-term treatment, electrolytes have to be monitored at least every three months.</p><p><strong>Serum sodium abnormalities</strong><br />Pre-treatment sodium abnormalities (hyponatraemia or hypernatraemia) must be corrected prior to initiation with tolvaptan therapy.</p><p><strong>Anaphylaxis</strong><br />In post-marketing experience, anaphylaxis (including anaphylactic shock and rash generalised) has been reported very rarely following administration of tolvaptan. This type of reaction occurred after the first administration of tolvaptan. Patients have to be carefully monitored during treatment. Patients with known hypersensitivity reactions to benzazepines or benzazepine derivatives (e.g. benazepril, conivaptan, fenoldopam mesylate or mirtazapine) may be at risk for hypersensitivity reaction to tolvaptan (see section 4.3).</p><p>If an anaphylactic reaction or other serious allergic reactions occur, administration of tolvaptan must be discontinued immediately and appropriate therapy initiated. Since hypersensitivity is a contraindication (see section 4.3) treatment must never be restarted after an anaphylactic reaction or other serious allergic reactions.</p><p><strong>Diabetes mellitus</strong><br />Diabetic patients with an elevated glucose concentration (e.g. in excess of 300 mg/dL) may present with pseudo-hyponatraemia. This condition must be excluded prior and during treatment with tolvaptan.</p><p>Tolvaptan may cause hyperglycaemia (see section 4.8). Therefore, diabetic patients treated with tolvaptan must be managed cautiously. In particular this applies to patients with inadequately controlled type II diabetes.</p><p><strong>Uric acid increases</strong><br />Decreased uric acid clearance by the kidney is a known effect of tolvaptan. In a double-blind, placebo-controlled trial of patients with ADPKD, potentially clinically significant increased uric acid (greater than 10 mg/dL) was reported at a higher rate in tolvaptan-patients (6.2 %) compared to placebo-treated patients (1.7 %). Adverse reactions of gout were reported more frequently in tolvaptan-treated patients (28/961, 2.9 %) than in patients receiving placebo (7/483, 1.4 %). In addition, increased use of allopurinol and other medicinal products used to manage gout were observed in the double-blind, placebo-controlled trial. Effects on serum uric acid are attributable to the reversible renal hemodynamic changes that occur in response to tolvaptan effects on urine osmolality and may be clinically relevant. However, events of increased uric acid and/or gout were not serious and did not cause discontinuation of therapy in the double-blind, placebo-controlled trial. Uric acid concentrations are to be evaluated prior to initiation of Prokitav therapy, and as indicated during treatment based on symptoms.</p><p><strong>Effect of tolvaptan on glomerular filtration rate (GFR)</strong><br />A reversible reduction in GFR has been observed in ADPKD trials at the initiation of tolvaptan treatment.</p><p><strong>Chronic Kidney Disease</strong><br />Limited safety and efficacy data are available for Prokitav in patients with CKD late stage 4 (eGFR&lt; 25 ml/min/1.73 m<sup>2</sup>). There are no data in patients with CKD stage 5. Tolvaptan treatment should be discontinued if renal insufficiency progresses to CKD stage 5.</p><p><strong>Prokitav contains lactose and sodium</strong><br />Prokitav contains lactose. Each tablet of Prokitav 60 mg and 30 mg Tablets contains 112 mg and 56 mg lactose; respectively. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Prokitav contains sodium. Each tablet of Prokitav 60 mg and 30 mg Tablets contains 1.82 mg and 0.91 mg sodium; respectively. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Effect of other medicinal products on the pharmacokinetics of tolvaptan</em></strong><br /><strong>CYP3A inhibitors</strong><br />Concomitant use of medicinal products that are moderate CYP3A inhibitors (e.g. amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil) or strong CYP3A inhibitors (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin) increase tolvaptan exposure.</p><p>Co-administration of tolvaptan and ketoconazole resulted in a 440 % increase in area under time-concentration curve (AUC) and 248 % increase in maximum observed plasma concentration (C<sub>max</sub>) for tolvaptan.</p><p>Co-administration of tolvaptan and fluconazole, a moderate CYP3A inhibitor, produced a 200 % and 80 % increase in tolvaptan AUC and C<sub>max</sub>, respectively.</p><p>Co-administration of tolvaptan with grapefruit juice, a moderate to strong CYP3A inhibitor, produced a doubling of peak tolvaptan concentrations (C<sub>max</sub>).</p><p>Dose reduction of tolvaptan is recommended for patients while taking moderate or strong CYP3A inhibitors (see section 4.2). Patients taking moderate or strong CYP3A inhibitors must be managed cautiously, in particular if the inhibitors are taken more frequently than once a day.</p><p><strong>CYP3A inducers</strong><br />Concomitant use of medicinal products that are potent CYP3A inducers (e.g. rifampicin) will decrease tolvaptan exposure and efficacy. Co-administration of tolvaptan with rifampicin reduces C<sub>max</sub> and AUC for tolvaptan by about 85 %. Therefore, concomitant administration of tolvaptan with potent CYP3A inducers (e.g. rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, and St. John&rsquo;s Wort) is to be avoided.</p><p><strong>Co-administration with medicinal products that increase serum sodium concentration</strong><br />There is no experience from controlled clinical trials with concomitant use of tolvaptan and hypertonic sodium chloride solution, oral sodium formulations, and medicinal products that increase serum sodium concentration. Medicinal products with high sodium content such as effervescent analgesic preparations and certain sodium containing treatments for dyspepsia may also increase serum sodium concentration. Concomitant use of tolvaptan with medicinal products that increase serum sodium concentration may result in a higher risk for developing hypernatraemia (see section 4.4) and is therefore not recommended.</p><p><strong>Diuretics</strong><br />Tolvaptan has not been extensively studied in ADPKD in combination with diuretics. While there does not appear to be a synergistic or additive effect of concomitant use of tolvaptan with loop and thiazide diuretics, each class of agent has the potential to lead to severe dehydration, which constitutes a risk factor for renal dysfunction. If dehydration or renal dysfunction becomes evident, appropriate action must be taken which may include the need to interrupt or reduce doses of tolvaptan and/or diuretics and increased fluid intake. Other potential causes of renal dysfunction or dehydration must be evaluated and addressed.</p><p><strong><em>Effect of tolvaptan on the pharmacokinetics of other products</em></strong><br /><strong>CYP3A substrates</strong><br />In healthy subjects, tolvaptan, a CYP3A substrate, had no effect on the plasma concentrations of some other CYP3A substrates (e.g. warfarin or amiodarone). Tolvaptan increased plasma levels of lovastatin by 1.3-to 1.5-fold. Even though this increase has no clinical relevance, it indicates tolvaptan can potentially increase exposure to CYP3A4 substrates.</p><p><strong>Transporter substrates</strong><br />P-glycoprotein substrates: <em>In-vitro</em> studies indicate that tolvaptan is a substrate and competitive inhibitor of P-glycoprotein (P-gp). Steady state digoxin concentrations were increased (1.3-fold in maximum observed plasma concentration [C<sub>max</sub>] and 1.2-fold in area under the plasma concentration-time curve over the dosing interval [AUC<sub>&tau;</sub>]) when co-administered with multiple once daily 60 mg doses of tolvaptan. Patients receiving digoxin or other narrow therapeutic P-gp substrates (e.g. dabigatran) must therefore be managed cautiously and evaluated for excessive effects when treated with tolvaptan.</p><p><strong>OATP1B1/OAT3/BCRP and OCT1: </strong><em>In-vitro</em> studies indicate that tolvaptan or its oxobutyric metabolite may have the potential to inhibit OATP1B1, OAT3, BCRP and OCT1 transporters. Co-administration of tolvaptan (90 mg) with rosuvastatin (5 mg), a BCRP substrate, increased rosuvastatin C<sub>max</sub> and AUC<sub>t</sub> of 54 % and 69 %, respectively. If BCRP substrates (e.g. sulfasalazine) are co-administered with tolvaptan, patients must be managed cautiously and evaluated for excessive effects of these medicinal products.</p><p>Administration of rosuvastatin (OATP1B1 substrate) or furosemide (OAT3 substrate) to healthy subjects with elevated oxobutyric acid metabolite (inhibitor of OATP1B1 and OAT3) plasma concentrations did not meaningfully alter the pharmacokinetics of rosuvastatin or furosemide. Statins commonly used in the tolvaptan phase 3 pivotal trial (e.g. rosuvastatin and pitavastatin) are OATP1B1 or OATP1B3 substrates, however no difference in adverse events profile was observed during the phase 3 pivotal trial for tolvaptan in ADPKD.</p><p>If OCT1 substrates (e.g. metformin) are co-administered with tolvaptan, patients must be managed cautiously and evaluated for excessive effects of these medicinal products.</p><p><strong>Diuretics or non-diuretic anti-hypertensive medicinal product(s)</strong><br />Standing blood pressure was not routinely measured in ADPKD trials. Therefore, a risk of orthostatic/postural hypotension due to a pharmacodynamic interaction with tolvaptan cannot be excluded.</p><p><strong>Co-administration with vasopressin analogues</strong><br />In addition to its renal aquaretic effect, tolvaptan is capable of blocking vascular vasopressin V2 receptors involved in the release of coagulation factors (e.g. von Willebrand factor) from endothelial cells. Therefore, the effect of vasopressin analogues such as desmopressin may be attenuated in patients using such analogues to prevent or control bleeding when co-administered with tolvaptan. It is not recommended to administer Prokitav with vasopressin analogues.</p><p><strong>Smoking and alcohol</strong><br />Data related to smoking or alcohol history in ADPKD trials are too limited to determine possible interactions of smoking or alcohol with efficacy and safety of ADPKD treatment with tolvaptan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />There are no or limited amount of data from the use of tolvaptan in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Prokitav is not recommended in women of childbearing potential not using contraception.</p><p>Prokitav is contraindicated during pregnancy (see section 4.3).</p><p><strong>Breast-feeding</strong><br />It is unknown whether tolvaptan is excreted in human breast milk. Studies in rats have shown excretion of tolvaptan in milk. A risk for the newborns/infants cannot be excluded. Prokitav is contraindicated during breast-feeding (see section 4.3).</p><p><strong>Fertility</strong><br />Studies in animals showed effects on fertility (see section 5.3). The potential risk for humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tolvaptan has minor influence on the ability to drive or use machines. When driving vehicles or using machines it has to be taken into account that occasionally dizziness, asthenia or fatigue may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong><br />The pharmacodynamically predictable and most commonly reported adverse reactions are thirst, polyuria, nocturia, and pollakiuria occurring in approximately 55 %, 38 %, 29 % and 23 % of patients, respectively. Furthermore, tolvaptan has been associated with idiosyncratic elevations of blood alanine aminotransferase (ALT; 4.4 %) and aspartate aminotransferases (AST; 3.1 %) with infrequent cases of concomitant elevations in bilirubin-total (BT; 0.2 %).</p><p><strong>Tabulated list of adverse reactions</strong><br />The incidences of the adverse drug reactions (ADRs) associated with tolvaptan therapy are tabulated below. The table is based on adverse reactions reported during clinical trials and/or post-marketing use.</p><p>All ADRs are listed by system organ class and frequency; very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse reactions is qualified as &quot;not known&quot;.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Very common </strong></p></td><td><p><strong>Common </strong></p></td><td><p><strong>Uncommon </strong></p></td><td><p><strong>Not known </strong></p></td></tr><tr><td><p><strong>Immune system disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Anaphylactic shock,</p><p>Generalised rash</p></td></tr><tr><td><p><strong>Metabolism and nutrition disorders </strong></p></td><td><p>Polydipsia</p></td><td><p>Dehydration,</p><p>Hypernatraemia,</p><p>Decreased appetite,</p><p>Hyperuricaemia,</p><p>Hyperglycaemia,</p><p>Gout</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Psychiatric disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>Insomnia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Nervous system disorders </strong></p></td><td><p>Headache,</p><p>Dizziness</p></td><td><p>Dysgeusia,</p><p>Syncope</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Cardiac disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>Palpitations</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>Dyspnoea</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Gastrointestinal disorders </strong></p></td><td><p>Diarrhoea,</p><p>Dry mouth</p></td><td><p>Abdominal pain,</p><p>Abdominal distension,</p><p>Constipation,</p><p>Dyspepsia,</p><p>Gastroesophageal reflux disease</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Hepatobiliary disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>Abnormal hepatic function</p></td><td><p>&nbsp;</p></td><td><p>Acute hepatic failure<sup>1</sup></p></td></tr><tr><td><p><strong>Skin and subcutaneous tissue disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>Dry skin,</p><p>Rash,</p><p>Pruritus,</p><p>Urticaria</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>Arthralgia,</p><p>Muscle spasms,</p><p>Myalgia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Renal and urinary disorders </strong></p></td><td><p>Nocturia,</p><p>Pollakiuria,</p><p>Polyuria</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>General disorders and administration site conditions </strong></p></td><td><p>Fatigue,</p><p>Thirst</p></td><td><p>Asthenia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Investigations </strong></p></td><td><p>&nbsp;</p></td><td><p>Alanine aminotransferase increased,</p><p>Aspartate aminotransferase increased,</p><p>Weight decreased,</p><p>Weight increased</p></td><td><p>Bilirubin increased</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><sup>1 </sup>Observed in post-marketing with tolvaptan in ADPKD. Liver transplantation was necessary.</p><p><strong>Description of selected adverse reactions</strong><br /><u>Laboratory results</u><br />Elevation (&gt; 3 &times; upper limit of normal [ULN]) of ALT was observed in 4.4 % (42/958) of patients on tolvaptan and 1.0 % (5/484) of patients on placebo, while elevation (&gt; 3 &times; ULN) of AST was observed in 3.1 % (30/958) of patients on tolvaptan and 0.8 % (4/484) patients on placebo in a double-blind, placebo-controlled trial in patients with ADPKD. Two (2/957, 0.2 %) of these tolvaptan treated-patients, as well as a third patient from an extension open label trial, exhibited increases in hepatic enzymes (&gt; 3 &times; ULN) with concomitant elevations in BT (&gt; 2 &times; ULN).</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&middot;&nbsp; Saudi Arabia<br />The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />&middot; Other GCC States<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single oral doses up to 480 mg (4 times the maximum recommended daily dose) and multiple doses up to 300 mg once daily for 5 days have been well tolerated in trials in healthy subjects. There is no specific antidote for tolvaptan intoxication. The signs and symptoms of an acute overdose can be anticipated to be those of excessive pharmacologic effect: a rise in serum sodium concentration, polyuria, thirst and dehydration/hypovolemia.</p><p>No mortality was observed in rats or dogs following single oral doses of 2,000 mg/kg (maximum feasible dose). A single oral dose of 2,000 mg/kg was lethal in mice and symptoms of toxicity in affected mice included decreased locomotor activity, staggering gait, tremor and hypothermia.</p><p>In patients with suspected tolvaptan overdose, assessment of vital signs, electrolyte concentrations, ECG and fluid status is recommended. Appropriate replacement of water and/or electrolytes must continue until aquaresis abates. Dialysis may not be effective in removing tolvaptan because of its high binding affinity for human plasma protein (&gt; 98 %).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Diuretics, vasopressin antagonists, ATC code: C03XA01.</p><p><strong>Mechanism of action</strong><br />Tolvaptan is a vasopressin antagonist that specifically blocks the binding of arginine vasopressin (AVP) at the V2 receptors of the distal portions of the nephron. Tolvaptan affinity for the human V2 receptor is 1.8 times that of native AVP.</p><p><strong>Pharmacodynamic effects</strong><br />The pharmacodynamic effects of tolvaptan have been determined in healthy subjects and subjects with ADPKD across CKD stages 1 to 4. Effects on free water clearance and urine volume are evident across all CKD stages with smaller absolute effects observed at later stages, consistent with the declining number of fully functioning nephrons. Acute reductions in mean total kidney volume were also observed following 3 weeks of therapy in all CKD stages, ranging from &minus;4.6 % for CKD stage 1 to &minus;1.9 % for CKD stage 4.</p><p><strong>Clinical efficacy and safety</strong><br />The primary focus of the clinical program for development of tolvaptan tablets for the treatment of ADPKD is a single pivotal, multi-national, phase 3, randomised, placebo-controlled trial in which the long-term safety and efficacy of oral split dose tolvaptan regimens (titrated between 60 mg/day and 120 mg/day) were compared with placebo in 1,445 adult subjects with ADPKD.</p><p>In total, 14 clinical trials involving tolvaptan have been completed worldwide in support of the ADPKD indication, including 8 trials in the US, 1 in the Netherlands, 3 in Japan, 1 in Korea, and the multinational phase 3 pivotal trial.</p><p>The phase 3 pivotal trial (TEMPO 3:4, 156-04-251) included subjects from 129 centres in the Americas, Japan, Europe and other countries. The primary objective of this trial was to evaluate the long-term efficacy of tolvaptan in ADPKD through rate of total kidney volume (TKV) change (normalised as percentage; %) for tolvaptan-treated compared with placebo-treated subjects. In this trial a total of 1,445 adult patients (age 18 years to 50 years) with evidence of rapidly-progressing, early ADPKD (meeting modified Ravine criteria, TKV &ge; 750 ml, estimated creatinine clearance &ge; 60 ml/min) were randomised 2:1 to treatment with tolvaptan or placebo. Patients were treated for up to 3 years.</p><p>Tolvaptan (n = 961) and placebo (n = 484) groups were well matched in terms of gender with an average age of 39 years. The inclusion criteria identified patients who at baseline had evidence of early disease progression. At baseline, patients had average estimated glomerular filtration rate (eGFR) of 82 ml/min/1.73 m<sup>2</sup> (Chronic Kidney Disease-Epidemiology Collaboration; CKD-EPI) with 79% having hypertension and a mean TKV of 1,692 ml (height adjusted 972 ml/m). Approximately 35 % of subjects were CKD stage 1, 48 % CKD stage 2, and 17 % CKD stage 3 (eGFRCKD-EPI). While these criteria were useful in enriching the study population with patients who were rapidly progressing, subgroup analyses based on stratification criteria (age, TKV, GFR, Albuminuria, Hypertension) indicated the presence of such risk factors at younger ages predicts more rapid disease progression.</p><p>The results of the primary endpoint, the rate of change in TKV for subjects randomised to tolvaptan (normalised as percentage, %) to the rate of change for subjects on placebo, were highly statistically significant. The rate of TKV increase over 3 years was significantly less for tolvaptan-treated subjects than for subjects receiving placebo: 2.80 % per year versus 5.51 % per year, respectively (ratio of geometric mean 0.974; 95 % CI 0.969 to 0.980; p &lt; 0.0001).</p><p>Pre-specified secondary endpoints were tested sequentially. The key secondary composite endpoint (ADPKD progression) was time to multiple clinical progression events of:</p><ol><li>Worsening kidney function (defined as a persistent [reproduced over at least 2 weeks] 25% reduction in reciprocal serum creatinine during treatment [from end of titration to last on-medicinal product visit])</li><li>Medically significant kidney pain (defined as requiring prescribed leave, last-resort analgesics, narcotic and anti-nociceptive, radiologic or surgical interventions)</li><li>Worsening hypertension</li><li>Worsening albuminuria</li></ol><p>The relative rate of ADPKD-related events was decreased by 13.5 % in tolvaptan-treated patients, (hazard ratio, 0.87; 95 % CI, 0.78 to 0.97; p = 0.0095).</p><p>The result of the key secondary composite endpoint is primarily attributed to effects on worsening kidney function and medically significant kidney pain. The renal function events were 61.4 % less likely for tolvaptan compared with placebo (hazard ratio, 0.39; 95 % CI, 0.26 to 0.57; nominal p &lt; 0.0001), while renal pain events were 35.8 % less likely in tolvaptan-treated patients (hazard ratio, 0.64; 95% CI, 0.47 to 0.89; nominal p = 0.007). In contrast, there was no effect of tolvaptan on either progression of hypertension or albuminuria.</p><p>TEMPO 4:4 is an open-label extension study that included 871 subjects that completed TEMPO 3:4 from 106 centres across 13 countries. This trial evaluated the effects of tolvaptan on safety, TKV and eGFR in subjects receiving active treatment for 5 years (early-treated), compared with subjects treated with placebo for 3 years, then switched to active treatment for 2 years (delayed-treated).</p><p>The primary end point for TKV did not distinguish a difference in change (&minus;1.7 %) over the 5-year treatment between early- and delayed-treated subjects at the pre-specified threshold of statistical significance (p = 0.3580). Both groups&rsquo; TKV growth trajectory was slowed, relative to placebo in the first 3 years, suggesting both early- and delayed- tolvaptan treated subjects benefitted to a similar degree.</p><p>A secondary endpoint testing the persistence of positive effects on renal function indicated that the preservation of eGFR observed by the end of the TEMPO 3:4 pivotal trial (3.01 to 3.34 ml/min/1.73 m<sup>2 </sup>at follow-up visits 1 and 2) could be preserved during open-label treatment. This difference was maintained in the pre-specified mixed effect model repeat measurement (MMRM) analysis (3.15 ml/min/1.73 m<sup>2</sup>, 95 %CI 1.462 to 4.836, p = 0.0003) and with sensitivity analyses where baseline eGFR data were carried forward (2.64 ml/min/1.73 m<sup>2</sup>, 95 % CI 0.672 to 4.603, p = 0.0086). These data suggest that tolvaptan can slow the rate of renal function decline, and that these benefits persist over the duration of therapy.</p><p>Longer term data are not currently available to show whether long-term therapy with tolvaptan continues to slow the rate of renal function decline and affect clinical outcomes of ADPKD, including delay in the onset of end-stage renal disease.</p><p>Genotyping for PKD1 and PKD2 genes was conducted in a majority of patients entering the open-label extension study (TEMPO 4:4) but the results are not yet known.</p><p>Following an additional 2 years of tolvaptan treatment, resulting in a total of 5 years on tolvaptan therapy no new safety signals were identified.</p><p>The phase 3, multi-centre, international, randomised-withdrawal, placebo-controlled, double-blind trial 156-13-210 compared the efficacy and safety of tolvaptan (45 mg/day to 120 mg/day) to placebo in patients able to tolerate tolvaptan during a five-week titration and run-in period on tolvaptan. The trial utilised a randomised withdrawal design, to enrich for patients that were able to tolerate tolvaptan for a 5-week, single-blind pre-randomisation period consisting of a 2-week titration period and 3-week run-in period. The design was used to minimise the impact of early discontinuation and missing data on trial endpoints.</p><p>A total of 1,370 patients (age 18 years to 65 years) with CKD with an eGFR between 25 and 65 ml/min/1.73 m<sup>2 </sup>if younger than age 56 years; or eGFR between 25 and 44 ml/min/1.73 m<sup>2</sup>, plus eGFR decline &gt;2.0 ml/min/1.73 m<sup>2</sup>/year if between age 56 years to 65 years were randomised to either tolvaptan (n = 683) or placebo (n = 687) and were treated for a period of 12 months.</p><p>For subjects randomised, the baseline, average eGFR was 41 ml/min/1.73 m<sup>2</sup> (CKD-EPI) and historical TKV, available in 318 (23 %) of subjects, averaged 2,026 ml. Approximately 5 %, 75 % and 20 % had an eGFR 60 ml/min/1.73 m<sup>2</sup> or greater (CKD stage 2), or less than 60 and greater than 30 ml/min/1.73 m<sup>2</sup> (CKD stage 3) or less than 30 but greater than 15 ml/min/1.73 m<sup>2</sup> (CKD stage 4), respectively. The CKD stage 3 can be subdivided further to stage 3a 30 %, (eGFR 45 ml/min/1.73 m<sup>2</sup> to less than 60 ml/min/1.73 m<sup>2</sup>) and stage 3b 45 %, (eGFR between 30 and 45 ml/min/1.73 m<sup>2</sup>).</p><p>The primary endpoint of the trial was the change in eGFR from pre-treatment baseline levels to post-treatment assessment. In patients treated with tolvaptan the reduction in eGFR was significantly less than in patients treated with placebo (p &lt; 0.0001). The treatment difference in eGFR change observed in this trial is 1.27 ml/min/1.73 m<sup>2</sup>, representing a 35 % reduction in the LS means of change in eGFR of &minus;2.34 ml/min/1.73 m<sup>2</sup> in tolvaptan group relative to a &minus;3.61 ml/min/1.73 m<sup>2</sup> in placebo group observed over the course of one year. The key secondary endpoint was a comparison of the efficacy of tolvaptan treatment versus placebo in reducing the decline of annualised eGFR slope across all measured time points in the trial. These data also showed significant benefit from tolvaptan versus placebo (p &lt; 0.0001).</p><p>Subgroup analysis of the primary and secondary endpoints by CKD stage found similar, consistent treatment effects relative to placebo for subjects in stages 2, 3a, 3b and early stage 4 (eGFR 25 to 29 ml/min/1.73 m<sup>2</sup>) at baseline.</p><p>A pre-specified subgroup analysis suggested that tolvaptan had less of an effect in patients older than 55 years of age, a small subgroup with a notably slower rate of eGFR decline.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Absorption</em></strong><br />After oral administration, tolvaptan is rapidly absorbed with peak plasma concentrations occurring about 2 hours after dosing. The absolute bioavailability of tolvaptan is about 56 %. Co-administration of tolvaptan with a high-fat meal increased peak concentrations of tolvaptan up to 2-fold but left AUC unchanged. Even though the clinical relevance of this finding is not known, the morning dose should be taken under fasted conditions to minimise the unnecessary risk of increasing the maximal exposure (see section 4.2).</p><p><strong><em>Distribution</em></strong><br />Following single oral doses of &ge; 300 mg, peak plasma concentrations appear to plateau, possibly due to saturation of absorption. Tolvaptan binds reversibly (98 %) to plasma proteins.</p><p><strong><em>Biotransformation</em></strong><br />Tolvaptan is extensively metabolised in the liver almost exclusively by CYP3A. Tolvaptan is a weak CYP3A4 substrate and does not appear to have any inhibitory activity. <em>In vitro </em>studies indicated that tolvaptan has no inhibitory activity for CYP3A. Fourteen metabolites have been identified in plasma, urine and faeces; all but one were also metabolised by CYP3A. Only the oxobutyric acid metabolite is present at greater than 10 % of total plasma radioactivity; all others are present at lower concentrations than tolvaptan. Tolvaptan metabolites have little to no contribution to the pharmacological effect of tolvaptan; all metabolites have no or weak antagonist activity for human V2 receptors when compared with tolvaptan. The terminal elimination half-life is about 8 hours and steady-state concentrations of tolvaptan are obtained after the first dose.</p><p><strong><em>Elimination</em></strong><br />Less than 1 % of intact active substance is excreted unchanged in the urine. Radio labelled tolvaptan experiments showed that 40 % of the radioactivity was recovered in the urine and 59 % was recovered in the faeces, where unchanged tolvaptan accounted for 32 % of radioactivity. Tolvaptan is only a minor component in plasma (3 %).</p><p><strong><em>Linearity/non-linearity</em></strong><br />Following single oral doses, C<sub>max</sub> values show less than dose proportional increases from 30 mg to 240 mg and then a plateau at doses from 240 mg to 480 mg. AUC increases linearly.</p><p>Following multiple once daily dosing of 300 mg, tolvaptan exposure was only increased 6.4-fold when compared to a 30 mg dose. For split-dose regimens of 30 mg/day, 60 mg/day and 120 mg/day in ADPKD patients, tolvaptan exposure (AUC) increases linearly.</p><p><strong><em>Pharmacokinetics in special populations</em></strong><br /><strong>Age</strong><br />Clearance of tolvaptan is not significantly affected by age.</p><p><strong>Hepatic impairment</strong><br />The effect of mildly or moderately impaired hepatic function (Child-Pugh classes A and B) on the pharmacokinetics of tolvaptan was investigated in 87 patients with liver disease of various origins. No clinically significant changes have been seen in clearance for doses ranging from 5 mg to 60 mg. Very limited information is available in patients with severe hepatic impairment (Child-Pugh class C).</p><p>In a population pharmacokinetic analysis in patients with hepatic oedema, AUC of tolvaptan in severely (Child-Pugh class C) and mildly or moderately (Child-Pugh classes A and B) hepatic impaired patients were 3.1-times and 2.3-times higher than that in healthy subjects.</p><p><strong>Renal impairment</strong><br />In a population pharmacokinetic analysis for patients with ADPKD, tolvaptan concentrations were increased, compared to healthy subjects, as renal function decreased below eGFR of 60 ml/min/1.73 m<sup>2</sup>. An eGFRCKD-EPI decrease from 72.2 to 9.79 (ml/min/1.73 m<sup>2</sup>) was associated with a 32 % reduction in total body clearance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential.</p><p>Teratogenicity was noted in rabbits given 1,000 mg/kg/day (2.6-times the exposure at the maximum human recommended dose of 120 mg/day). No teratogenic effects were seen in rabbits at 300 mg/kg/day (1.2-times the exposure at the maximum human recommended dose of 120 mg/day).</p><p>In a peri- and post-natal study in rats, delayed ossification and reduced pup bodyweight were seen at the high dose of 1,000 mg/kg/day.</p><p>Two fertility studies in rats showed effects on the parental generation (decreased food consumption and body weight gain, salivation), but tolvaptan did not affect reproductive performance in males and there were no effects on the foetuses. In females, abnormal oestrus cycles were seen in both studies.</p><p>The no observed adverse effect level (NOAEL) for reproduction in females (100 mg/kg/day) was about 4.4-times the exposure at the maximum human recommended dose of 120 mg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactose</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline cellulose</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Croscarmellose sodium</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maize starch</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colloidal silicone dioxide</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate.</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FD&amp;C blue</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium lauryl sulfat</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/Aclar-aluminum blisters.</p><p>Pack size: Prokitav 60 mg and 30 mg Tablets: 56 Tablets (28 tablets of the higher strength + 28 tablets of the lower strength).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                16 December 2024 

 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>